Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
FAST LINE HOLDING Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 49,285 | +2,20 % | Pharma-Schock: Umstrukturierung im Kampf gegen Eli Lilly - Novo Nordisk streicht 9000 Stellen | © Foto: Christian Schultz/dpaNovo Nordisk startet einen radikalen Umbau mit massiven Stellenstreichungen, um trotz wachsendem Druck im Adipositasmarkt seine Spitzenposition zu sichern.Der dänische Pharmariese... ► Artikel lesen | |
AURORA CANNABIS | 4,195 | -0,59 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CANOPY GROWTH | 1,164 | -5,06 % | Canopy Growth Confirms Tom Stewart As CFO | ||
TILRAY BRANDS | 1,025 | -0,73 % | Tilray Brands, Inc.: Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain "Sprits 26", Elevates Craft Portfolio with Modern Blue Dream Release | ||
VERTEX PHARMACEUTICALS | 327,50 | -0,74 % | Vertex Pharmaceuticals Incorporated: Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Research... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | Malawi: RBM Unveils Bold Plan to Safeguard Forex Gains Beyond Tobacco Season | ||
ARZNEIWERK AG VIDA | 0,169 | 0,00 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin... ► Artikel lesen | |
CRONOS GROUP | 2,192 | +0,55 % | Cronos Group Inc.: Cronos Group Reports 2025 Second Quarter Results | Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
ORGANIGRAM GLOBAL | 1,490 | +0,68 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 6,570 | +1,47 % | Green Thumb Launches $50M Buyback: Time to Get Bullish on the Stock? | ||
MYDECINE INNOVATIONS GROUP | 0,001 | 0,00 % | Aquis Stock Exchange: Withdrawal from Trading - Mydecine Innovations Group Inc. | Aquis Stock Exchange
Aquis Stock Exchange: Withdrawal from Trading 02-Apr-2025 / 07:00 GMT/BST
The issuer is solely responsible for the content of this... ► Artikel lesen | |
SANTHERA PHARMACEUTICALS | 15,400 | 0,00 % | Santhera Pharmaceuticals Holding AG: Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE (Vamorolone) in India | Pratteln, Switzerland, 29 August, 2025 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE®... ► Artikel lesen | |
AMARIN | 12,500 | 0,00 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 43,200 | +2,86 % | Nektar Therapeutics: ResPEG zeigt vielversprechendes Potenzial bei Autoimmunerkrankungen |